Development and preclinical assessment of ROR2-specific CAR-T cells for the treatment of clear cell renal cell carcinoma and multiple myeloma
- Weitere Titel
-
Entwicklung und präklinische Evaluation ROR2-spezifischer CAR-T Zellen zur Behandlung des klarzelligen Nierenzellkarzinoms und des Multiplen Myeloms
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Würzburg, Universität Würzburg, Dissertation, 2023
- Schlagwort
-
Krebs
CAR-T-Zell-Therapie
Immuntherapie
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2024
- Urheber
- Beteiligte Personen und Organisationen
-
Hudecek, Michael
Herrmann, Thomas
Einsele, Hermann
Rader, Christoph
- DOI
-
10.25972/OPUS-31039
- URN
-
urn:nbn:de:bvb:20-opus-310399
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:41 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Weber, Justus C.
- Hudecek, Michael
- Herrmann, Thomas
- Einsele, Hermann
- Rader, Christoph
- Universität Würzburg
Entstanden
- 2024
Ähnliche Objekte (12)
The role of PBRM1 in clear cell renal cell carcinoma
Genomic landscape of clear cell sarcoma
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-implications for myeloma bone disease
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
Regional differences in clear cell metastatic renal cell carcinoma patients across the USA
Dynamic fine-tuning of CAR-T cell therapy
Dynamic fine-tuning of CAR-T cell therapy
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
CIK Cells and HDAC Inhibitors in Multiple Myeloma
The role of PBRM1 in clear cell renal cell carcinoma
Genomic landscape of clear cell sarcoma
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-implications for myeloma bone disease
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
Regional differences in clear cell metastatic renal cell carcinoma patients across the USA
Dynamic fine-tuning of CAR-T cell therapy
Dynamic fine-tuning of CAR-T cell therapy
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma
CIK Cells and HDAC Inhibitors in Multiple Myeloma
The role of PBRM1 in clear cell renal cell carcinoma
Genomic landscape of clear cell sarcoma
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cells
Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-implications for myeloma bone disease
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma
Regional differences in clear cell metastatic renal cell carcinoma patients across the USA
Dynamic fine-tuning of CAR-T cell therapy
Dynamic fine-tuning of CAR-T cell therapy
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma